Hematologic engraftment and immune reconstitution posttransplantation with
anti-B1 purged autologous bone marrow
KC Anderson, J Ritz, T Takvorian, F Coral, H Daley, BC Gorgone, AS Freedman, GP Canellos, SF Schlossman and LM Nadler
Hematologic engraftment and immune reconstitution were examined in patients
who received cyclophosphamide and total body irradiation therapy followed
by infusion of autologous bone marrow purged with anti- B1 monoclonal
antibody (MoAb) and complement as therapy for non- Hodgkin's lymphoma.
Hematologic engraftment was prompt with return of greater than or equal to
0.5 X 10(3)/microL granulocytes and greater than or equal to 2 X
10(4)/microL platelets at a median of 26 and 29 days posttransplant,
respectively. Immunologic reconstitution, in contrast, was prolonged.
Normal numbers of circulating B cells were consistently noted by five
months posttransplant, whereas return of normal immunoglobulin levels in
some patients did not occur for one year. Normal numbers of T cells were
evident within the first month posttransplant, but a reversed T4:T8 ratio
persisted in some patients up to three years. In vitro responses of either
B cells to triggers of activation or of T cells to mitogens and antigens
were not normal for at least three months posttransplant. Natural killer
(NK) cells predominated early after transplant and may demonstrate
cytotoxicity against tumor cells. Our studies demonstrate that
transplantation with anti-B1 purged autologous bone marrow results in
complete hematologic and delayed immunologic engraftment. No significant
acute or chronic clinical toxicities have been observed.
Volume 69,
Issue 2,
pp. 597-604,
02/01/1987
Copyright © 1987 by The American Society of Hematology
